NCT04377659 2025-05-28Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 InfectionMemorial Sloan Kettering Cancer CenterPhase 2 Terminated9 enrolled 8 charts
NCT04361552 2020-06-18Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)Emory UniversityPhase 3 Withdrawn